We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West is now celebrating the one-year anniversary of its Integrated Solutions initiative, known as Simplify the Journey™. Throughout 2019, we socialized the program through marketing materials and face-to-face conversations with customers. Now it’s time to reflect on the lessons we’ve learned — and to look forward to the opportunities on the horizon.
As injectable medicines have evolved, customers have expressed a need for partners that can offer a more holistic approach encompassing the entire lifecycle of an injectable medicine, from early clinical development to commercialization. The Integrated Solutions initiative from West, now celebrating its one-year anniversary, does exactly that, bringing together West’s primary packaging, device, analytical, regulatory and contract manufacturing expertise in a single-source solution.
A New Approach for All Customers
The Integrated Solutions initiative elevates West’s role as a partner and collaborator. Our goal is to complement, not duplicate, the functional capabilities of our customers. This enables them to focus on their core competencies while relying on West for services they may not have or plan to have inhouse. As such, with Integrated Solutions in place, we can offer something to every customer, regardless of their size or where their products sit in the development lifecycle.
According to Jennifer Riter, Senior Director, Analytical Services, “We always knew smaller pharma companies could benefit from this type of bundled solution because they simply don’t have the internal resources to accommodate the full range of services West offers. But we were excited to learn how many larger companies were willing, even eager, to engage us in conversations about how we could help.”
The willingness of customers to engage about an Integrated Solutions approach is directly related to the changes and challenges taking place across the industry. “There are a number of trends driving drug and device manufacturing,” Riter points out. “The continued focus on combination products, as well as many pipelines containing complex molecules, are just a few examples.” As companies struggle to respond to these drivers, they face gaps in experience and knowledge. “Integrated Solutions affords West the opportunity to fill these gaps, to leverage the expertise we’ve acquired over nearly 100 years of manufacturing containers, closures and delivery devices for injectable medicines.”
The Journey Continues
Integrated Solutions is a year old, but in reality, West has been offering many of these services independently to customers for over 20 years. Formalizing the name and providing more structure to the program allows us to truly share with our customers what we have learned and how this knowledge can help address our customer’s needs and challenges.
Looking forward, Integrated Solutions will continue to evolve based on industry needs and challenges. As it does, one thing is certain: West is committed to the program because an integrated, comprehensive approach is required for the rapidly changing pharmaceutical landscape.
As Riter points out, “Ultimately, Integrated Solutions is about bringing together the right drugs, devices, and services needed to ensure the best overall patient experience. But the complexities involved to deliver that ultimate experience are significant. It takes collaboration — between manufacturers and external providers like West — and an interconnected suite of services to ensure a product makes it to the market and is used by the people who need it.”
Simplify the Journey™ is a trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
Container closure integrity (CCI) is a critical factor every drug manufacturer and compounder is required to achieve. To achieve CCI, one must consider factors such as vial material, blowback, and stopper design. One vital factor – too often an afterthought – is the aluminum seal.
The impact of a cancer diagnosis can be stressful. Questions such as “how will I tell my family?”, “how will I afford to pay my bills?”, “will I ever work again?” and even “will I survive?” <span>are at the forefront of the patient’s mind as they process their diagnosis and begin treatment</span>. So, how can the patient experience with treatment be supported? By offering the best quality of care.
Polymeric container systems are not new to the pharmaceutical industry, and their benefits in terms of break resistance, cosmetic quality and dimensional precision have been recognized by many companies around the world who have chosen to use a polymer vial or syringe.
Pharmaceutical industry focus on issues of extractables and leachables from packaging/delivery systems began during the mid-1990’s. Since then, regulatory agencies have become more educated, and drug product formulations have become more complex, which makes the need for a robust extractables and leachables program that much more critical. Failure to properly evaluate extractables and leachables has had a negative impact on many pharmaceutical companies, e.g., late-stage stability failures, submission delays, and recalls. To avoid this, the question is – where to start?
Pharmaceutical closures used in aseptic environments must be introduced in a sterile state. The most common methods to sterilize rubber closures (e.g., stoppers) are autoclaving (saturated steam) and gamma irradiation. Both methods can influence chemical (e.g., extractables profile) and physical/functional properties (e.g., break-loose and extrusion forces). Therefore, it is important to choose the right method.
English
Chinese
